Pyxis Oncology Inc
NASDAQ:PYXS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.51
6.59
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Pyxis Oncology Inc
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
| Market Cap | EV/EBIT | ||||
|---|---|---|---|---|---|
| US |
|
Pyxis Oncology Inc
NASDAQ:PYXS
|
112.4m USD | 0.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -216 722.5 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
316.8B USD | 23.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
145.1B USD | 31 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119B USD | 26 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
113.2B USD | 10 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -501.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.4B AUD | 25.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.7B USD | 18 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -53.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
34.3B EUR | -75.8 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.
You don't have any saved screeners yet
